BacLab

Regenerative Peptides Hub: Cellular Repair, Angiogenesis, and Soft-Tissue Models

Editorial note: this article summarises published research on BPC-157, TB-500, LL-37 and KPV. Baclabs does not sell BPC-157, TB-500, LL-37, KPV or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.

“Regenerative peptides” is a marketing category rather than a pharmacological one. It groups four short amino-acid chains that share a claim, tissue repair, but very little else: BPC-157, a synthetic fragment of a gastric protein; TB-500, a fragment of the actin-binding protein thymosin beta-4; LL-37, the only human cathelicidin antimicrobial peptide; and KPV, a three-residue tail of alpha-melanocyte-stimulating hormone. This hub explains how each is thought to work, what the animal and human evidence actually shows, where the regulators stand in September 2026, and how the reconstitution arithmetic works for the freeze-dried vials these compounds are sold in.

The honest headline is that none of the four is a licensed medicine anywhere, and the strength of evidence runs from “several controlled human trials of a pharmaceutical formulation” (LL-37 and thymosin beta-4 in wound and eye indications) to “rodent data only, plus a two-person infusion pilot” (BPC-157). Keeping those distinctions clear is the point of this page.

Four supporting articles go deeper: the BPC-157 and TB-500 “Wolverine stack”, a BPC-157 reconstitution and route guide, LL-37 and KPV, and purity, certificates of analysis and UK regulation.

What regenerative peptides are supposed to do

Tissue repair follows a recognisable sequence: haemostasis and inflammation, then proliferation (new blood vessels, fibroblast migration, collagen deposition), then remodelling. Each of the four peptides has been proposed to act on a different stage of that sequence.

  • Angiogenesis and vascular signalling. BPC-157 is reported in rodent models to increase VEGFR2 expression and activate the VEGFR2-Akt-eNOS pathway, with a close relationship to the nitric oxide (NO) system [1]. Thymosin beta-4 promotes endothelial cell migration and vessel formation through its actin-binding domain [2].
  • Cell migration and cytoskeleton. Thymosin beta-4 is the major G-actin sequestering molecule in mammalian cells; by binding monomeric actin it regulates the polymerisation that cells need to move into a wound [2][3].
  • Antimicrobial activity and immune modulation. LL-37 kills bacteria by disrupting membranes and also acts as an “alarmin”, recruiting and activating immune cells, promoting angiogenesis and re-epithelialisation [4].
  • Anti-inflammatory signalling. KPV inhibits NF-κB and MAP kinase activation at nanomolar concentrations and is taken into gut epithelial and immune cells by the peptide transporter PepT1 [5].

Every one of these mechanisms was characterised in cells or animals. Whether the same effects occur at the doses and routes used by people buying vials online is, for most of the four, unknown.

BPC-157: the most studied and the least tested in humans

BPC-157 (Body Protection Compound 157) is a 15-amino-acid sequence (GEPPPGKPADDAGLV) synthesised to match part of a protein found in human gastric juice. It is described as “stable gastric pentadecapeptide” because it survives in human gastric juice for more than 24 hours, unlike most peptides [6]. The overwhelming majority of the literature comes from Predrag Sikirić’s group in Zagreb, spanning three decades of rat studies in which BPC-157 accelerated healing of transected Achilles tendon, detached tendon-to-bone, crushed muscle, ligament and gastrointestinal lesions [1][7][8].

The rodent dosing is remarkably consistent: 10 µg/kg or 10 ng/kg given intraperitoneally once daily, or 0.16 µg/mL in drinking water, with the authors reporting equivalent effects across routes and no toxicity (an LD1 could not be reached) [1]. A separate Chinese pharmacokinetic study in rats and beagle dogs found an elimination half-life under 30 minutes, intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, and rapid breakdown to amino acids [9].

Human data are thin. Ulcerative colitis trials run by Pliva in Croatia in the early 2000s were never published as controlled results; a 2025 pilot infused up to 20 mg intravenously in two healthy adults and reported no adverse effects [10]; and a single-centre retrospective series of intra-articular injections for knee pain relied on subjective outcomes [11]. Two 2025 reviews in orthopaedic journals reach the same verdict: promising preclinical signals, no published randomised controlled human trial [11][12]. The FDA’s own briefing document for its July 2026 advisory committee found “insufficient clinical safety information to characterize the safety profile” [13].

TB-500 and thymosin beta-4: a fragment with a borrowed evidence base

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein present in nearly every mammalian cell. Its wound-healing activity has been mapped to short segments: the N-terminal Ac-SDKP region, which supports cell survival, and the central actin-binding domain LKKTET (residues 17–23), which drives angiogenesis and migration [3]. “TB-500” as sold online is usually the synthetic heptapeptide Ac-LKKTETQ, not the full protein, although some vendors label full-length Tβ4 the same way.

The human trials belong to the full protein, developed by RegeneRx as RGN-137 (dermal gel) and RGN-259 (eye drops). A 72-patient phase 2 in venous stasis ulcers met its safety endpoint; the mid-dose 0.03% gel healed 33% of ulcers versus 24% on placebo, a difference that was not statistically significant [14]. In neurotrophic keratopathy, 0.1% RGN-259 drops five times daily produced complete epithelial healing in 6 of 10 patients versus 1 of 8 on placebo at day 29 (p = 0.0656; trial stopped early for slow recruitment) [15]. The ARISE-3 dry-eye phase 3 missed its primary endpoints [16]. In other words, even the pharmaceutical version has yet to prove efficacy in a phase 3 trial, and none of this was done with the LKKTETQ fragment.

The only published study to test BPC-157 and TB-500 together, a 2026 rat Achilles tendon model, found TB-500 alone (60 µg/kg/day) improved load to failure and histology, BPC-157 alone (10 µg/kg/day) produced non-significant improvements, and the combination “did not confer additional benefits compared to either agent alone” [17]. The Wolverine stack article works through that result.

LL-37 and KPV: antimicrobial and anti-inflammatory candidates

LL-37 is the 37-residue active form of human cathelicidin hCAP18, produced by neutrophils and epithelial cells [4]. It is the one peptide in this cluster with repeated placebo-controlled human data for a topical formulation: a 34-participant first-in-man trial in hard-to-heal venous leg ulcers, where 0.5 mg/mL applied twice weekly gave a healing rate roughly six-fold that of placebo (p = 0.003) [18], and a 148-patient phase 2b follow-up [19]. Both used topical application to open wounds, which says nothing about subcutaneous injection of LL-37, the route most vendor listings imply.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH. In mouse colitis models, KPV in drinking water reduced inflammation and cytokine expression, and the effect depended on PepT1 uptake [5][20]. There are no published human trials of KPV for any indication. The LL-37 and KPV article covers both in detail.

Peptide Origin Best human evidence Licensed anywhere? WADA status
BPC-157 Synthetic, gastric protein fragment 2-person IV pilot; retrospective knee series No Prohibited, S0 non-approved substances [21]
TB-500 (Tβ4 fragment) Residues 17–23 of thymosin beta-4 None for the fragment; phase 2–3 for full Tβ4 (topical/ocular) No Prohibited, S2 growth factor modulators (“thymosin-β4 and its derivatives, e.g. TB-500”) [21]
LL-37 Human cathelicidin Phase 1/2 and 2b topical trials in leg ulcers No Not specifically named
KPV C-terminal tripeptide of α-MSH None No Not specifically named

Regulatory position in 2026

United States. On 29 September 2023 the FDA moved BPC-157, thymosin beta-4 fragment (LKKTETQ), cathelicidin LL-37, KPV and 15 other peptides to Category 2 of its interim 503A bulk drug substances list, the category for substances that “raise significant safety risks”, which removed them from pharmacy compounding [22][23]. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend adding BPC-157, KPV and TB-500 to the 503A list, against the uniform opposition of FDA’s own scientists [24]. That vote is non-binding; it would need notice-and-comment rulemaking before anything changes, and none of the four peptides is an approved drug.

United Kingdom. Regulation 46 of the Human Medicines Regulations 2012 prohibits selling, supplying or offering to supply an unauthorised medicinal product [25]. The MHRA has stated that it disregards “for research purposes” labelling where it is being used to avoid medicines regulation, and in April 2026 confirmed it was reviewing peptide websites for enforcement [26]. Buying a vial for personal use is not itself an offence; selling one that is presented for human use is.

Sport. BPC-157 is prohibited at all times under S0 (non-approved substances) and thymosin-β4 and its derivatives, TB-500 named explicitly, under S2 of the WADA Prohibited List [21]. Tested athletes should treat every product in this cluster as a doping risk.

Adverse effects and unknowns

The published rodent studies report no toxicity for BPC-157, and the two-person infusion pilot recorded no adverse effects [1][10]. That is not the same as safety. The FDA’s concerns are immunogenicity (an immune response to the peptide or its aggregates, amplified by impurities and parenteral routes), unknown effects of long-term use, and the fact that synthetic products vary in characterisation [13]. One theoretical concern follows from the mechanism itself: a peptide that promotes angiogenesis could in principle support the blood supply of a tumour. This has not been demonstrated as a clinical harm, but it has not been ruled out either, because no study has looked. For LL-37, the same peptide is implicated in psoriasis and lupus pathogenesis [4], which is a reason for caution about systemic dosing.

Reconstitution: the part that is actually well defined

Whatever the evidence for the peptide, the arithmetic of turning a freeze-dried vial into a measurable solution is fixed. Concentration equals vial mass divided by diluent volume; each unit on a U-100 insulin syringe is 0.01 mL.

Formula: mass (mcg) ÷ diluent (mL) = mcg/mL; mcg/mL × 0.01 = mcg per insulin unit.

Vial Bacteriostatic water added Concentration mcg per U-100 unit Units for 250 mcg
BPC-157 5 mg 1 mL 5,000 mcg/mL 50 mcg 5
BPC-157 5 mg 2 mL 2,500 mcg/mL 25 mcg 10
TB-500 5 mg 2 mL 2,500 mcg/mL 25 mcg 10
TB-500 10 mg 2 mL 5,000 mcg/mL 50 mcg 5
KPV 10 mg 2 mL 5,000 mcg/mL 50 mcg 5
LL-37 5 mg 2.5 mL 2,000 mcg/mL 20 mcg 12.5

The 250 mcg column is an illustration of the arithmetic, not a recommended dose; literature-reported figures are discussed with attribution in the BPC-157 protocol guide. Multi-dose vials need a preserved diluent, because a vial punctured repeatedly with plain sterile water has no defence against microbial contamination; see bacteriostatic versus sterile water for the distinction. Baclabs supplies UK-stocked bacteriostatic water (0.9% benzyl alcohol, 30 mL vials) and the reconstitution guide has the full method. Once reconstituted, peptides are typically refrigerated and the bacteriostatic water itself is used for up to 28 days after first puncture; the reasoning is in storage and shelf life.

How to read this cluster

If you take one thing from this hub, take the hierarchy of evidence. Licensed medicines have dose-ranging human trials and a Summary of Product Characteristics; none of these four qualify. Thymosin beta-4 and LL-37 have controlled human trials of specific pharmaceutical formulations for specific topical indications, which is meaningful but non-transferable to a vial of powder injected subcutaneously. BPC-157 has an unusually large and unusually single-source animal literature and effectively no controlled human data. KPV has mouse data. Sourcing quality is a separate problem, covered in the purity and regulation article.

Frequently asked questions

What are regenerative peptides?

A marketing term for short peptides proposed to accelerate tissue repair, chiefly BPC-157, TB-500 (a thymosin beta-4 fragment), LL-37 and KPV. They act on different mechanisms, from angiogenesis to actin binding to antimicrobial and anti-inflammatory signalling. None is licensed as a medicine in the UK, EU or US, and human trial evidence ranges from limited to absent depending on the compound.

Is BPC-157 backed by human clinical trials?

No published randomised controlled trial exists. The evidence is almost entirely rat studies from one research group, a two-person intravenous safety pilot published in 2025, and a small retrospective knee-injection series. The FDA’s 2026 briefing document concluded there was insufficient clinical safety information to characterise its safety profile, even though an advisory committee later voted narrowly to allow compounding.

Is TB-500 the same as thymosin beta-4?

Not quite. Thymosin beta-4 is a 43-amino-acid protein. TB-500 as commonly sold is a synthetic seven-residue fragment (Ac-LKKTETQ) covering its actin-binding site. Human trials of RGN-137 and RGN-259 used the full protein topically or as eye drops. The fragment has no human trials, and WADA lists “thymosin-β4 and its derivatives, e.g. TB-500” as prohibited.

Are regenerative peptides legal to buy in the UK?

Possessing them for personal use is not an offence, but selling or supplying an unauthorised medicinal product breaches regulation 46 of the Human Medicines Regulations 2012. The MHRA has said it ignores “research use only” labels where they are used to sidestep medicines law and is reviewing peptide websites. Nothing in this cluster is prescribable in the UK as a licensed product.

Why do peptide vials need bacteriostatic water?

Freeze-dried peptides are supplied as multi-dose vials that are punctured repeatedly over days or weeks. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth in the vial between draws and is why it is used for up to 28 days after first puncture. Plain sterile water has no preservative and is intended for single use.

Which regenerative peptide has the strongest evidence?

By human-trial standards, LL-37 and full-length thymosin beta-4, both tested topically in placebo-controlled wound trials. Even so, thymosin beta-4 missed its phase 3 dry-eye endpoints and LL-37 is not licensed. BPC-157 has the largest animal literature but essentially no controlled human data. KPV has none at all.

References

  1. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Seiwerth S, Sikiric P et al., Frontiers in Pharmacology, 2021
  2. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005 (PMID 16099219)
  3. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. 2010 (PMID 20179146)
  4. The human cathelicidin LL-37 – a pore-forming antibacterial peptide and host-cell modulator. 2016 (PMID 26556394)
  5. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008 (PMC2431115)
  6. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Sikiric P et al., Current Pharmaceutical Design, 2020 (PMID 32329684)
  7. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003 (PMID 14554208)
  8. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 2006 (PMID 16583442)
  9. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. He L et al., Frontiers in Pharmacology, 2022
  10. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025 (PMID 40131143)
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. 2025 (PMC12446177)
  12. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Vasireddi N et al., 2025 (PMID 40756949)
  13. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting: BPC-157. US FDA, July 2026
  14. RegeneRx Reports Phase II Venous Stasis Trial Results. Fierce Biotech, 2009
  15. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences, 2023 (PMC9820614)
  16. RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial. RegeneRx / PR Newswire, 2021
  17. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Biçer et al., Joint Diseases and Related Surgery, 2026 (PMID 42542926)
  18. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Grönberg A et al., Wound Repair and Regeneration, 2014 (PMID 25041740)
  19. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Mahlapuu M et al., Wound Repair and Regeneration, 2021 (PMC9298190)
  20. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008 (PMID 18092346)
  21. The Prohibited List. World Anti-Doping Agency, 2026 (S0 non-approved substances; S2 growth factors and growth factor modulators)
  22. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US FDA
  23. 503A Bulk Drug Substances Categories Update, September 29 2023. Alliance for Pharmacy Compounding, 2023
  24. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. US FDA, 2026
  25. The Human Medicines Regulations 2012, Regulation 46: Requirement for authorisation. legislation.gov.uk
  26. Grey-market peptides: what pharmacists need to know. The Pharmacist, April 2026 (MHRA statements)

Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.